SONN Dividend: Sonnet Biotherapeutics Holdings Inc Yield Insights

Breakdown	TTM	09/30/2024	09/30/2023	09/30/2022	09/30/2021	09/30/2020
Revenue	1	0	0	0	0	0
Revenue Growth (YoY)	--	--	--	--	--	-100%
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	7	6	7	8	8	7
Research & Development	7	5	11	21	16	9
Operating Expenses	14	11	18	30	25	17
Other Non Operating Income (Expenses)	0	0	--	0	0	--
Pretax Income	-13	-7	-18	-29	-24	-24
Income Tax Expense	0	--	--	--	--	--
Net Income	-13	-7	-18	-29	-24	-65
Net Income Growth	86%	-61%	-38%	21%	-63%	282%
Shares Outstanding (Diluted)	3.96	0.65	0.12	0.2	0.08	0.03
Shares Change (YoY)	530%	405%	-35%	150%	167%	--
EPS (Diluted)	-3.41	-11.35	-145.11	-148.6	-312.25	-2,186.66
EPS Growth	-73%	-92%	-2%	-52%	-86%	-89%
Free Cash Flow	-10	-8	-21	-28	-22	-15
Free Cash Flow Per Share	-2.52	-12.21	-161.78	-140	-275	-500
Gross Margin	--	--	--	--	--	--
Operating Margin	-1,300%	0%	0%	0%	0%	0%
Profit Margin	-1,300%	0%	0%	0%	0%	0%
Free Cash Flow Margin	-1,000%	0%	0%	0%	0%	0%
EBITDA	-13	-11	-18	-29	-25	-17
EBITDA Margin	-1,300%	0%	0%	0%	0%	0%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-13	-11	-18	-29	-25	-17
EBIT Margin	-1,300%	0%	0%	0%	0%	0%
Effective Tax Rate	0%	--	--	--	--	--

Sonnet Biotherapeutics Holdings Inc (SONN) Price